For research use only. Not for therapeutic Use.
ARN-509 (Cat No.:I005661) is a next-generation androgen receptor inhibitor used in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). It works by blocking the androgen receptor signaling pathway, which is essential for the growth and survival of prostate cancer cells. ARN-509 prevents androgen receptor activation by androgens, leading to decreased tumor cell proliferation. Its high specificity and potency reduce the risk of off-target effects. Apalutamide has been shown to significantly improve progression-free survival in patients, offering an effective treatment for advanced prostate cancer.
| Catalog Number | I005661 |
| CAS Number | 956104-40-8 |
| Synonyms | Apalutamide; ARN509；ARN 509； |
| Molecular Formula | C21H15F4N5O2S |
| Purity | 98% |
| Target | AR |
| Target Protein | |
| Solubility | DMSO 15 mg/mL Ethanol 5 mg/mL |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| Overview of Clinical Research | Originator: University of California System<br /> |
| IC50 | IC50: 16 nM (Androgen receptor) |
| IUPAC Name | 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide |
| InChI | InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31) |
| InChIKey | HJBWBFZLDZWPHF-UHFFFAOYSA-N |
| SMILES | CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F |
| Reference | 1: Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, Alumkal |
